Skip to content

MBX Biosciences, Inc.

MBX

CIK 0001776111

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$88.43M
−40.5% YoY Q1 May 2026
EPS Diluted (TTM)
−$2.42
+59.1% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$81.88M
Q1 May 2026
Cash
$45.21M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
47.6M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings